Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Dilip Shanghvi to continue as the Executive Chairman of the Board
Subscribe To Our Newsletter & Stay Updated
